SPH Stock Overview
Produces, distributes, and exports pharmaceutical products in Europe, Bulgaria, and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 0/6 |
| Past Performance | 2/6 |
| Financial Health | 6/6 |
| Dividends | 3/6 |
Community vs My Fair Value
Create NarrativeSelect a narrative for quick price alerts from the community, or create your own.
My Notes
Capture your thoughts, links and company narrative
Sopharma AD Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | лв12.40 |
| 52 Week High | лв14.70 |
| 52 Week Low | лв11.40 |
| Beta | -0.023 |
| 1 Month Change | -0.80% |
| 3 Month Change | -4.62% |
| 1 Year Change | -15.36% |
| 3 Year Change | 24.62% |
| 5 Year Change | 49.40% |
| Change since IPO | 65.33% |
Recent News & Updates
Recent updates
Shareholder Returns
| SPH | PL Pharmaceuticals | PL Market | |
|---|---|---|---|
| 7D | 0.4% | -1.5% | 2.9% |
| 1Y | -15.4% | 22.9% | 7.3% |
Return vs Industry: SPH underperformed the Polish Pharmaceuticals industry which returned 22.9% over the past year.
Return vs Market: SPH underperformed the Polish Market which returned 7.3% over the past year.
Price Volatility
| SPH volatility | |
|---|---|
| SPH Average Weekly Movement | 8.9% |
| Pharmaceuticals Industry Average Movement | 5.1% |
| Market Average Movement | 5.5% |
| 10% most volatile stocks in PL Market | 10.5% |
| 10% least volatile stocks in PL Market | 3.4% |
Stable Share Price: SPH's share price has been volatile over the past 3 months compared to the Polish market.
Volatility Over Time: SPH's weekly volatility (9%) has been stable over the past year, but is still higher than 75% of Polish stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1933 | 5,379 | Ognian Donev | www.sopharmagroup.com |
Sopharma AD produces, distributes, and exports pharmaceutical products in Europe, Bulgaria, and internationally. The company operates through Production of Pharmaceutical Products; Distribution of Pharmaceutical Products (Goods); and Others. It offers Carsil to treat liver disease; Tempalgin and Analgin, a painkiller; Tabex, drug used for smoking secession; Tribestan, drug used for stimulation of the male reproductive system; Broncholytin, which is used to suppress cough; Nivalin, used for diseases of the peripheral nervous system; Methylprednisolon, for severe allergies and life-threatening conditions; Vitamin C; Valeriana, used to reduce the stress; and medical devices, such as gauzes, compresses, and dressing.
Sopharma AD Fundamentals Summary
| SPH fundamental statistics | |
|---|---|
| Market cap | zł2.04b |
| Earnings (TTM) | zł174.19m |
| Revenue (TTM) | zł4.37b |
11.7x
P/E Ratio0.5x
P/S RatioIs SPH overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| SPH income statement (TTM) | |
|---|---|
| Revenue | лв2.05b |
| Cost of Revenue | лв1.60b |
| Gross Profit | лв451.40m |
| Other Expenses | лв369.49m |
| Earnings | лв81.91m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
Apr 30, 2025
| Earnings per share (EPS) | 0.49 |
| Gross Margin | 21.97% |
| Net Profit Margin | 3.99% |
| Debt/Equity Ratio | 36.3% |
How did SPH perform over the long term?
See historical performance and comparisonDividends
2.6%
Current Dividend Yield33%
Payout RatioCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/02/16 06:54 |
| End of Day Share Price | 2025/02/14 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Sopharma AD is covered by 2 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Mihail Dimitrov | First Financial Brokerage House |
| Bram Buring | Wood & Company |